Advanced search
Publication Cover
Platelets Volume 34, 2023 - Issue 1
Submit an article Journal homepage
3,570
Views
3
CrossRef citations to date
0
Altmetric
Research Article

Recombinant human thrombopoietin (rhTPO) of different dosing regimens for refractory/relapsed primary immune thrombocytopenia: a multicenter, randomized controlled trial and pharmacokinetics study

Xiaofan Liu1 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin Key Laboratory of Gene Therapy for Blood Diseases, CAMS Key Laboratory of Gene Therapy for Blood Diseases, Tianjin, ChinaORCID Iconhttps://orcid.org/0000-0002-9911-4491View further author information
ORCID Icon,
Yusheng Bai2 Department of Hematology, Traditional Chinese Medical Hospital of Xinjiang Uygur Autonomous Region, Urumqi, Xinjiang, ChinaView further author information
,
Tao Wang3 Department of Hematology, The First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, Henan, ChinaView further author information
,
Yanping Song4 Department of Hematology, Xi’an Central Hospital, Xi’an, Shaanxi, ChinaView further author information
,
Feng Sun5 Department of Hematology, First Affiliated Hospital, Heilongjiang University of Chinese Medicine, Harbin, Heilongjiang, ChinaView further author information
,
Ruixiang Xia6 Department of Hematology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui Province, ChinaView further author information
,
Feiyue Zhu7 Department of Hematology, Loudi Central Hospital, Loudi, Hunan, ChinaView further author information
,
Jun Ma8 Department of Hematology, Harbin Institute of Hematology and Oncology, Harbin, Heilongjiang, ChinaView further author information
,
Quanyi Lu9 Department of Hematology, Zhongshan Hospital, Xiamen University, Xiamen, Fujian, ChinaView further author information
,
Xu Ye10 Department of Hematology, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, ChinaView further author information
,
Xinrong Zhan11 Department of Hematology, Xinxiang Central Hospital, Xinxiang, Henan, ChinaView further author information
,
Linjie Li12 Department of Hematology, Lishui Central Hospital, Lishui, Zhejiang, ChinaView further author information
,
Xinhong Guo13 Department of Hematology, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang Uygur Autonomous Region, ChinaView further author information
,
Shuqin Cheng14 Department of Hematology, Guangzhou Panyu Central Hospital, Guangzhou, Guangdong, ChinaView further author information
,
Yan Li15 Department of Hematology, The First Hospital of China Medical University, Shenyang, Liaoning, ChinaView further author information
,
Zhiqiang Guo16 Department of Hematology, Zhengzhou Central Hospital, Zhengzhou, Henan, ChinaView further author information
,
Youhua Chen17 Department of Hematology, Renmin Hospital of Wuhan University, Hubei General Hospital, Wuhan, Hubei, ChinaView further author information
,
Shenxian Qian18 Department of Hematology, Affiliated Hangzhou First People’s Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, ChinaView further author information
,
Ling Qin19 Department of Hematology, The First Affiliated Hospital of Henan Technology University, Luoyang, Henan, ChinaView further author information
,
Qing Zhang20 Department of Hematology, Guangdong Second Provincial General Hospital, Guangzhou, Guangdong, ChinaView further author information
,
Sunqiong Cao21 Medical Department, Shenyang Sunshine Pharmaceuticals Co. Ltd, Shenyang, Liaoning, ChinaView further author information
&
Renchi Yang1 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin Key Laboratory of Gene Therapy for Blood Diseases, CAMS Key Laboratory of Gene Therapy for Blood Diseases, Tianjin, ChinaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-3741-8518View further author information
ORCID Icon show all
Article: 2157806 | Received 02 Aug 2022, Accepted 07 Dec 2022, Published online: 03 Jan 2023

Reprints and Permissions

This is an open access article distributed under the terms of the Creative Commons CC BY license, which permits unrestricted use, distribution, reproduction in any medium, provided the original work is properly cited.

You are not required to obtain permission to reuse this article in part or whole.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.